Prosecution Insights
Last updated: November 04, 2026
Application No. 16/994,283

USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION

Final Rejection §102§103§112
Filed
Aug 14, 2020
Priority
Sep 18, 2014 — EU 14185397.8 +2 more
Examiner
HASAN, KHALEDA B
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Provost Fillows Foundatio Scholars & The Other Members Of Board Of The College Of The Holy
OA Round
6 (Final)
59%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
80 granted / 135 resolved
-0.7% vs TC avg
Strong +49% interview lift
Without
With
+49.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
27 currently pending
Career history
165
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
33.7%
-6.3% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 135 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status This action is written in response to applicant’s correspondence received 10/14/2026. Claims 1 and 9 are amended. Claims 1, 3, and 5-9 are currently pending. Claims 5-8 are withdrawn from prosecution as being drawn to non-elected subject matter. Accordingly, claims 1, 3, and 9 are examined herein. Election/Restrictions Applicant's elected Group II – claims 1-7 with traverse in the reply filed 12/20/2022. Claims 5-8 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 12/20/22. The restriction requirement mailed 09/22/2022 is still deemed proper, as detailed in the Non-Final Office Action mailed 3/2/2023. Applicant's elected species Psoriasis in claim 3, Cathepsin G in claims 4 and 7, and Cathepsin G inhibitor I in claim 5 without traverse in the reply filed 12/20/2022. The non-elected species in claim 3 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 12/20/22. Claim Objections Claims 1 and 9 are objected to because of the following informalities: claim 1 part a) recites the limitation: “a peptide consisting of 3 to 8 consecutive amino acids, wherein the 3 to 8 consecutive amino acids comprise: Glu-Pro-Phe (EPF), Ala-Phe-Leu-Phe (AFLF) (SEQ ID NO:7), Lys-Ala-Leu (KAL), Phe-Leu-Phe-CMK (FLF-CMK), Glu-Pro-Phe-CMK (EPF-CMK), or Ala-Phe-Leu-Phe-CMK (AFLF (SEQ ID NO:7)-CMK). It is unclear if the phrase “consisting of” limits only the number of amino acids required by the peptide such that it only consists of between 3 and 8 consecutive amino acids, but also allows chemical modifications or it also limits the peptide to amino acids with no chemical modifications. If the peptide can also be a derivative comprising or consisting of chemical modifications, the claim language should reflect that. Claim 1 part b), claim 9 part a) and claim 9 part b) are objected to for similar reasons. Appropriate correction is required. Broadest Reasonable Interpretation For the purposes of compact prosecution, claim 1 part a), 1 part b), 9 part a), and 9 part b) are being interpreted to limit the number and sequence of the amino acids listed while allowing the -CMK group where listed. Claim Rejections - 35 USC § 112 - withdrawn Rejection of claim 9 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn in view of Applicant’s amendment to claims filed 10/14/2026 to limit part b) to 3 amino acids. Claim Rejections - 35 USC § 102 - withdrawn Rejection of claims 1, 3, and 9 under 35 U.S.C. 102(a)(2) as being anticipated by Kim et al. (US20140348859A1; published November 27, 2014, priority to January 10, 2013) in withdrawn in view of Applicant’s amendment to claims filed 10/14/2026 adding “-CMK” to “FLF” in part a) of claims 1 and 9. Claim Rejections - 35 USC § 103 – new necessitated by amendment In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 3, and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Kim et al. (US20140348859A1; published November 27, 2014, priority to January 10, 2013), in view of Cooley et al. (The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry, 40(51), 15762-15770; published 11/30/2001; cited in the 892) and Powers et al. (published 11/8/2002 Cite No. 35 in the IDS filed 9/1/2023). This is a new rejection necessitated by amendment of claims 1 and 9 to add “-CMK” to FLF in part a) and to limit the length of the peptide in part b) from “3 to 7” to “3” consecutive amino acids. Kim’s disclosure is directed to generating and using recombinant constructs of alpha-1 antitrypsin (AAT) having superior properties to commercially available AAT compositions for therapeutic uses (see entire document). Kim further teaches that recombinant AAT constructs can be isolated for use for any AAT-related activity, for example, as an anti-inflammatory agent, an immune modulator and/or a serine protease inhibitor (see abstract). Regarding claims 1 and 9, Kim teaches a method of treatment for inflammatory skin disorders in a subject in need thereof comprising administering an effective amount of the serine protease inhibitor alpha-1 antitrypsin (AAT) (see abstract and paras 0004-0005 and 0063-0064). Kim teaches that the serine protease inhibitor AAT can comprise fragments and subfragments as small as “about 5 AAs”, which encompasses lengths of 4 amino acids and 6 amino acids (see para 0005, claim 1). Kim teaches treatments including the pentapeptides of AAT comprising the 3 consecutive amino acids of Phe-Leu-Phe (FLF) (see paras 0096 and 0099-0105; SEQ ID NOs: 8-11 and 15-16). However, Kim does not specifically teach the peptide consisting of only 3 amino acids or comprising a CMK group. Cooley’s disclosure is directed to inhibitors of serine protease, including elastase, (entire document). Cooley teaches that MNEI (monocyte/neutrophil elastase inhibitor) plays a regulatory role at extravascular sites to limit inflammatory damage due to proteases of cellular origin (see abstract). Regarding claims 1 and 9, Cooley teaches the tripeptide Suc-Phe-Leu-Phe-SBzl (Suc-FLF-SBzl), which teaches part a) of claims 1 and 9 as a substrate to measure protease inhibition activity and teaches that the tripeptide was the most sensitive (see p. 15763-15734; Table 1). Powers’ disclosure is directed to a review of irreversible inhibitors of serine, cysteine, and threonine proteases (entire document). Powers teaches the importance of proteases in various disease states including inflammation (abstract). Regarding claims 1 and 9, Powers teaches protease inhibitor design and that chloromethyl ketone (CMK) derivatives can be used as irreversible inhibitors of serine and cysteine proteases (pp. 4644-4547; Table 2). Powers further teaches that the CMK derivatives are widely used in vivo and in animals (p. 4648). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the Kim’s tetrapeptide protease inhibitor with the tripeptide Suc-FLF-SBzl taught in Cooley because it would have amounted to a simple substitution of known small peptide inhibitors to obtain predictable results of inhibiting protease activity. One would have been motivated to use the tripeptide Suc-FLF-SBzl because Cooley shows that is the most sensitive of several peptides tested. It would have been further obvious to have modified the Suc-FLF-SBzl peptide to substitute the chemical groups with a CMK group as taught in Powers to because Powers teaches that the peptidyl CMK derivatives are irreversibly serine and peptide inhibitors and are widely used in vivo and in animals, making them suitable for treating a subject (p. 4648). One would have been motivated to optimize the treatment of an inflammatory disease in a subject with protease inhibitor short peptides. One would have had a reasonable expectation of success because Kim, Cooley, and Powers are directed to inhibitors of proteases and peptide derivatives. Thus, the claimed invention as a whole is prima facie obvious. Regarding claim 3, Kim teaches AAT therapy for treatment of plaque psoriasis, guttate psoriasis pustular psoriasis, erythrodermic psoriasis, inverse psoriasis, psoriatic arthritis, lichen planus, Bullous pemphigoid, dermatomyositis, and dermatitis (see paras 0063-0064). Therefore the invention as a whole would have been prima facie obvious to one of ordinary skill in the art before the effective filing date. Response to Arguments Applicant's arguments filed 10/14/2026 have been fully considered but they are not persuasive. Applicant’s arguments, pages 2-7, are directed towards the 102 rejection of record over now amended claims 1 and 9. A new 103 rejection necessitated by amendment is detailed above. Therefore, the arguments are moot and will not be addressed. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KHALEDA B HASAN whose telephone number is (571)272-0239. The examiner can normally be reached IFP, Monday - Friday 7:30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached at (571) 270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KHALEDA B HASAN/Examiner, Art Unit 1636 /BRIAN WHITEMAN/Primary Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Show 7 earlier events
Jan 03, 2025
Response Filed
Apr 14, 2025
Final Rejection mailed — §102, §103, §112
Oct 14, 2025
Request for Continued Examination
Oct 16, 2025
Response after Non-Final Action
Jan 28, 2026
Non-Final Rejection mailed — §102, §103, §112
Jul 28, 2026
Response Filed
Oct 14, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774347
ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19
1y 6m to grant Granted Oct 27, 2026
Patent 12758573
RNA ACTION INHIBITOR AND USE THEREOF
4y 7m to grant Granted Oct 13, 2026
Patent 12747441
RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES
3y 2m to grant Granted Sep 29, 2026
Patent 12742172
ENGINEERED DNA MOLECULE FOR CODING RNA
1y 6m to grant Granted Sep 22, 2026
Patent 12697400
GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY
2y 3m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+49.0%)
3y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 135 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month